3,7,12-trihydroxycholest-24-enoic acid: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
ID Source | ID |
---|---|
PubMed CID | 5284237 |
CHEBI ID | 186850 |
MeSH ID | M0164532 |
Synonym |
---|
3alpha,7alpha,12alpha-trihydroxycholest-24-enoic acid |
3,7,12-trihydroxycholest-24-enoic acid |
cholest-24-en-26-oic acid, 3,7,12-trihydroxy-, (3alpha,5beta,7alpha,12alpha)- |
24-oh-thca |
3,7,12-trihydroxy-5beta-cholest-24-en-26-oic acid |
LMST04030064 , |
3alpha,7alpha,12alpha-trihydroxy-5beta-24e-cholesten-26-oic acid |
5226-26-6 |
(e,6r)-2-methyl-6-[(3r,5s,7r,8r,9s,10s,12s,13r,14s,17r)-3,7,12-trihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]hept-2-enoic acid |
CHEBI:186850 |
(24e)-3a,7a,12a-trihydroxy-5b-cholest-24-en-27-oic acid |
Class | Description |
---|---|
bile acid | Any member of a group of hydroxy-5beta-cholanic acids occuring in bile, where they are present as the sodium salts of their amides with glycine or taurine. In mammals bile acids almost invariably have 5beta-configuration. |
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 1 (20.00) | 18.7374 |
1990's | 3 (60.00) | 18.2507 |
2000's | 1 (20.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.80) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 0 (0.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 5 (100.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |